Carmat SAS is a France-based Company engaged in the development and production of heart prosthesis.
enter price:25.8; stop-loss 23.30; target price 33.60.
Carmat's RSI looks strong and shows upwards momentum, therefore a drastic trend reversal or corrective pullback are unlikely to occur in the near future.
DMI the indicator in these situation can't be easily...
Carmat SA, producer of first ever artificial heart, obtained permission to sell it in the EU as a bridge to a heart transplant.
It also pans to treat the first patients in the US in the first quarter 2021 “based on ongoing discussions with the FDA”.
In the EU only estimated annual sales may amount to 700 million EUR by 2030.
Thus, I expect market cap to increase...
